Chart Wise: Tucson (KTUS) VOR or TACAN Rwy 2

If you fly in yourself, you might just use the VOR or TACAN RWY 12 for an approach. If you're not already a subscriber, what ...
Business Wire

Owlet Announces Strategic DME Partnership with PromptCare to Expand Distribution of Pediatric Pulse Oximeter, BabySat

LEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a new strategic partnership with PromptCare, a leading ...
The Globe and Mail

Vor Biopharma CDO Departs, Transition Support Planned

Vor Biopharma ( (VOR)) just unveiled an update. On December 31, 2025, Vor Biopharma Inc. entered into a separation agreement with its Chief Development Officer, Dr. Qing Zuraw, following her decision ...
Investing

Vor Bio raises $150 million in private placement to fund clinical trials

Vor Bio did not engage a placement agent for this transaction. In other recent news, Vor Biopharma Inc. announced a repricing of certain stock options for its employees and executives. The exercise ...
Yahoo Finance

Vor Bio Announces $150 Million Private Placement

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a ...
Hosted on MSN

Vor Biopharma approves stock option repricing plan

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Seeking Alpha

Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing

JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
MarketWatch

Vor Biopharma Shares Fall in Premarket on Pricing of $100M Stock Offering

Vor Biopharma shares fell sharply Tuesday in premarket trading after the company priced its $100 million offering below recent trading prices. Shares traded 31% lower ahead of the morning bell at ...
The American Journal of Managed Care

Faricimab Effective, Durable in Real-World DME Outcomes

Faricimab offers extended dosing intervals for DME, reducing injection frequency compared to traditional anti-VEGF therapies. The study showed improvements in CST and visual acuity in both ...
Healio

Study investigates current status, unmet needs in DME management

Please provide your email address to receive an email when new articles are posted on . A large cohort study showed high prevalence of bilateral diabetic macular edema at first visit. The intensity of ...